Antihistamine

ApprovedSmall molecule

Arrowhead Pharmaceuticals

Antihistamine is one of 462 small molecule programs targeting Allergy. It is currently in Approved.

Indications

Total Trials

Active Trials

461

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

Pemphigus VulgarisActive, not recruiting

Esophageal Squamous Cell CarcinomaRecruiting

Esophageal CancerActive, not recruiting

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Allergic RhinitisActive, not recruiting

Primary Progressive Multiple SclerosisActive, not recruiting

Acute Otitis MediaActive, not recruiting

Breast CancerActive, not recruiting

AllergyPhase 2

Active, not recruiting

Pemphigus VulgarisPhase 3

Active, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Primary Progressive Multiple SclerosisPhase 3

Active, not recruiting

Acute Otitis MediaPhase 3

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Antihistamine

Arrowhead Pharmaceuticals

Approved

1 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Exercise

NCT05206227

Q3 2027

Phase 3Active, not recruiting

Primary Progressive Multiple Sclerosis

NCT04548999

Phase 2Active, not recruiting

Medulloblastoma

NCT04743661

Q1 2028

Recruiting

SARS Cov 2 Infection

NCT05504057

Recruiting

Influenza

NCT04367883

Q3 2028

Phase 3Active, not recruiting

Multiple Sclerosis

NCT04544436

Clinical

Trials by Indication[1]

Chronic Hepatitis4 trials

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02604199·58 enrolled

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02738008·12 enrolled

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1·NCT02797522·47 enrolled

Show 1 more trial

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02577029·79 enrolled

Primary Progressive Multiple Sclerosis2 trials

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04548999·769 enrolled

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Completed· Roche logo

Roche·Phase 3·NCT02688985·131 enrolled

SARS CoV 2 Infection1 trial

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

Recruiting·CConsorci Sanitari de Terrassa··NCT05504057·140,660 enrolled

Multiple Sclerosis1 trial

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04544436·864 enrolled

Asthma1 trial

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Completed·—·Phase 2·NCT04179461·21 enrolled

17 more indications

Refractory1 trial

Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops

Withdrawn·VVanderbilt University·N/A·NCT01661777

Allergy1 trial

Peanut Allergy Oral Immunotherapy Desensitization

Completed·HHamilton Health Sciences Corporation·Phase 2·NCT01601522·43 enrolled

Acute otitis media1 trial

Acute Otitis Media: Adjuvant Therapy to Improve Outcome

Completed·NNational Institute on Deafness and Other Communication Disorders (NIDCD)·Phase 3·NCT00000363

Efficacy and Safety1 trial

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Completed·CCinnagen·Phase 3·NCT06406153·12 enrolled

Exercise1 trial

Histamine as a Molecular Transducer of Adaptation to Exercise

Active, not recruiting·UUniversity of Oregon·Phase 1·NCT05206227·80 enrolled

Rheumatoid Arthritis1 trial

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 4·NCT01382940·351 enrolled

Chronic Hepatitis B Virus Infection1 trial

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02604212·32 enrolled

Influenza1 trial

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Recruiting·CConsorci Sanitari de Terrassa··NCT04367883·3,000 enrolled

Bladder Cancer1 trial

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03258593·15 enrolled

Breast Cancer1 trial

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Completed· Eisai logo

Eisai·Phase 1·NCT04568902·33 enrolled

Randomized1 trial

Randomized Trial for Mixed Acute Rejection

Completed·UUniversity of Cincinnati·Phase 2·NCT00771875·30 enrolled

Medulloblastoma1 trial

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active, not recruiting·PPediatric Brain Tumor Consortium·Phase 2·NCT04743661·62 enrolled

Irritable Bowel Syndrome1 trial

Prevalence of Antihistamine Responsive Irritable Bowel Syndrome With Diarrhea

Unknown status·UUniversity of Cincinnati··NCT04612803·100 enrolled

Trial1 trial

A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject

Completed· Otsuka logo

Otsuka·Phase 1·NCT01737931·120 enrolled

Allergic Rhinitis1 trial

Acupuncture for Nasal Congestion in Allergic Rhinitis

Completed·JJohanna Maria Vermeulen·N/A·NCT05709977·11 enrolled

Pemphigus Vulgaris1 trial

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Terminated· GSK logo

GSK·Phase 3·NCT02613910·1 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05319730·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Antihistamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antihistamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antihistamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Arrowhead Pharmaceuticals

Antihistamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Chronic Hepatitis4 trials

Primary Progressive Multiple Sclerosis2 trials

SARS CoV 2 Infection1 trial

Multiple Sclerosis1 trial

Asthma1 trial

Refractory1 trial

Allergy1 trial

Acute otitis media1 trial

Efficacy and Safety1 trial

Exercise1 trial

Rheumatoid Arthritis1 trial

Chronic Hepatitis B Virus Infection1 trial

Influenza1 trial

Bladder Cancer1 trial

Breast Cancer1 trial

Randomized1 trial

Medulloblastoma1 trial

Irritable Bowel Syndrome1 trial

Trial1 trial

Allergic Rhinitis1 trial

Pemphigus Vulgaris1 trial

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News